Levetiracetam in three cases of progressive myoclonus epilepsy

Pharmacy World and Science

Volumn 29, Issue 3, 2007, Pages 164-166

  Papacostas, Savvas ^a   Kkolou, Elena ^a   Papathanasiou, Eleftherios ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

Epilepsy; Levetiracetam; Progressive Myoclonus; Unverricht Lundborg epilepsy

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; PIRACETAM; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; ARTICLE; ATAXIA; CASE REPORT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSMETRIA; ELECTROENCEPHALOGRAM; EPILEPSY; EVOKED SOMATOSENSORY RESPONSE; FEMALE; GENERALIZED EPILEPSY; HAIR LOSS; HOSPITALIZATION; HUMAN; MALE; MENTAL DETERIORATION; MYOCLONUS EPILEPSY; NOCTURNAL SEIZURE; PHYSICAL EXAMINATION; QUALITY OF LIFE; RETINITIS PIGMENTOSA; RHESUS INCOMPATIBILITY; SEIZURE; SLOW BRAIN WAVE; SYNCOPE; TENDON REFLEX; TONIC CLONIC SEIZURE; TREMOR;

ACTIVITIES OF DAILY LIVING; ADULT; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PIRACETAM; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNVERRICHT-LUNDBORG SYNDROME;

EID: 34249899672     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9039-1     Document Type: Article

References (10)

1. Crest C, Dupond S, Leguern E et al. Levetiracetam in progressive myoclonic epilepsy. Neurology 2004;62:640-3.
2. Kinrions P, Ibrahim N, Murphy K et al. Efficacy of levetiracetam in a patient with Undverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003;60:1394-5.
3. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45:678-81.
4. Pennacchio LA, Lehesjoki A-E, Stone NE et al. Mutations in the gene encoding cystatin B in progressive myoclonic epilepsy (EPM1). Science 1996;271:1731-4.
5. Genton P, Gelisse P. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;57:1144-5.
6. 2+ current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
7. Rigo JM, Hans G, Nguyen L et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated current. Br J Pharmacol 2002;136:659-72.
8. Lynch BA, Lambeng L, Nocka K et al. The synaptic vescicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861-6.
9. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83.
10. Kasteleijn-Nolst Trenite DGA, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord 2003;5 Suppl 1:S39-S44.